Lyell Immunopharma

Developing next-generation T-cell therapies for patients with solid tumors.

Discussion
BiotechnologyOncology lyell.com ↗

Company facts

Founded
2018
Employees
300
Headquarters
United States
Type
Public
Listed
NASDAQ: LYEL